Fundraising FoxCirc Biosciences
Chicago, US · Founded 2019 · 3 known investors
Find your way into Circ Biosciences
Sign up to see every warm intro you have to Circ Biosciences
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Circ Biosciences team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
CiRC Biosciences develops cellular reprogramming therapies that convert fibroblasts directly into specific neurons and cell types lost in degenerative eye and brain diseases. Its programs target dopaminergic neurons in Parkinson's disease, GABAergic interneurons in refractory epilepsy, and orexin neurons in treatment-resistant narcolepsy, building on prior retinal cell replacement work.
Founders & leadership
DP
Darien ParhadExecutive
PM
Patrick MorrisExecutive
SC
Sai ChavalaNamed on SEC filing
Board
TC
Timothy CunniffBoard director
AG
Antonio GraciasBoard directorFounder, Chief Executive Officer & Chief Investment Officer at Valor Equity Partners
JA
Jeffrey AroninBoard director
Investors · 3
Reported raises · per SEC filings
Form D private placements$24.1M disclosed across 3 rounds · 2020–2024
▶$250KraisedOct 2024 · 1 investors · BiotechnologyRule 506(b)
▶$250KraisedOct 2024 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Darien ParhadExecutive Officer
- Timothy CunniffDirector
- Patrick MorrisExecutive Officer, Director
- Sai ChavalaDirector
- Antonio GraciasDirector
- Jeffrey AroninDirector
- Offering amount
- $250K
- Amount sold
- $250K
- Minimum investment
- $250K
- First sale
- Feb 2024
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$7MraisedMay 2024 · 19 investors · BiotechnologyRule 506(b)
▶$7MraisedMay 2024 · 19 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Darien ParhadExecutive Officer
- Timothy M. CunniffDirector
- Sai ChavalaDirector
- Patrick J MorrisExecutive Officer, Director
- Jeffrey S. AroninDirector
- Antonio J. GraciasDirector
- Offering amount
- $7M
- Amount sold
- $7M
- First sale
- Apr 2024
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$16.8MraisedDec 2020 · 3 investors · BiotechnologyRule 506(b)
▶$16.8MraisedDec 2020 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Patrick J MorrisExecutive Officer, Director
- Darien ParhadExecutive Officer
- Jeffrey S. AroninDirector
- Antonio J. GraciasDirector
- Sai ChavalaDirector
- Timothy M. CunniffDirector
- Offering amount
- $16.8M
- Amount sold
- $16.8M
- First sale
- Oct 2020
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Circ Biosciences do?
- CiRC Biosciences develops cellular reprogramming therapies that convert fibroblasts directly into specific neurons and cell types lost in degenerative eye and brain diseases. Its programs target dopaminergic neurons in Parkinson's disease, GABAergic interneurons in refractory epilepsy, and orexin neurons in treatment-resistant narcolepsy, building on prior retinal cell replacement work.
- Who are Circ Biosciences's investors?
- Circ Biosciences's investors include Paragon Biosciences LLC, Portal Innovations, Valor Equity Partners.
- How much funding has Circ Biosciences raised?
- Circ Biosciences has disclosed $24.1M raised across 3 rounds.
- Where is Circ Biosciences headquartered?
- Circ Biosciences is headquartered in Chicago, US.